Should You Continue to Hold EW Stock in Your Portfolio?
Edwards Lifesciences leans on growth in Surgical Structural Heart, TAVR and TMTT, though macro pressures and litigation continue to weigh on margins.
Edwards Lifesciences Corporation (EW) Analyst/Investor Day Transcript
Edwards Lifesciences Corporation (EW) Analyst/Investor Day Transcript
Is the Options Market Predicting a Spike in Edwards Lifesciences Stock?
Investors need to pay close attention to EW stock based on the movements in the options market lately.
Edwards Lifesciences Corporation (EW) Q3 2025 Earnings Call Transcript
Edwards Lifesciences Corporation ( EW ) Q3 2025 Earnings Call October 30, 2025 5:00 PM EDT Company Participants Mark Wilterding - Vice President of Investor Relations Bernard Zovighian - CEO & Director Scott Ullem - Corporate VP & CFO Daniel Lippis - Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) Daveen Chopra - Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies Conference Call Participants Travis Steed - BofA Securities, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Matthew Taylor - Jefferies LLC, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Presentation Operator Greetings, and welcome to the Edwards Lifesciences' Third Quarter 2025 Conference Call. [Operator Instructions] Please note, this conference is being recorded.
Edwards Lifesciences (EW) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Edwards Lifesciences beats quarterly estimates on strength in heart devices
Edwards Lifesciences beat Wall Street estimates for third-quarter results on Thursday, driven by strong demand for its artificial heart valves and other medical devices, with shares rising about 3% in extended trading.
Edwards Lifesciences CFO Scott Ullem to step down by mid-2026
Edwards Lifesciences said on Thursday its Chief Financial Officer Scott Ullem will step down by mid-2026 and remain in an advisory role after a successor is named.
Exploring Analyst Estimates for Edwards Lifesciences (EW) Q3 Earnings, Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Robust TAVR Growth to Drive Edwards Lifesciences' Q3 Earnings
Strong TAVR demand and expanding valve therapies are set to power EW's Q3 results despite lower EPS estimates.
Edwards Lifesciences: Inflection Incoming, But When?
Edwards Lifesciences Corporation remains a market leader in transcatheter heart valve technologies, with strong secular tailwinds and consistent revenue growth. EW's TMTT segment is the fastest-growing area, but margin pressures, stagnating EPS, and declining returns limit near-term upside potential. Despite a robust balance sheet and ongoing share buybacks, EW's valuation appears stretched relative to its growth and industry peers.
EW Stock Climbs on Q2 Earnings & Revenue Beat, Margins Down
Edwards Lifesciences posts a second-quarter 2025 earnings and revenue beat, with strong growth in TAVR and TMTT segments despite margin pressure.
Edwards Lifesciences Corporation (EW) Q2 2025 Earnings Call Transcript
Edwards Lifesciences Corporation (NYSE:EW ) Q2 2025 Earnings Conference Call July 24, 2025 5:00 PM ET Company Participants Mark Wilterding - Vice President of Investor Relations Bernard Zovighian - CEO & Director Scott Ullem - Corporate VP & CFO Larry Wood - Corporate VP and Group President of TAVR & Surgical Structural Heart Daveen Chopra - Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies Conference Call Participants Robert Marcus - JPMorgan Chase & Co, Research Division Travis Steed - Bank of America Larry Biegelsen - Wells Fargo Securities, LLC, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Matthew Taylor - Jefferies LLC, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Christopher Pasquale - Nephron Research LLC Operator Greetings, and welcome to the Edwards Lifesciences Second Quarter 2025 Results Conference Call. [Operator Instructions].
